Evidence map›Paper›PMID 40337022›Full record

ArticleIndian journal of surgical oncology2025

Preoperative Platelet/Albumin Ratio Predicts Morbidity and Mortality in Patients with Retroperitoneal Liposarcoma.

Dorian Yarih Garcia-Ortega, Julián Diaz-Rico, Ana Paulina Melendez-Fernandez, Constanza Palma-Rebollar, Kuauhyama Luna-Ortiz

Abstract read
In one paragraph

Article in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dorian Yarih Garcia-OrtegaSurgical Oncology, Skin, Soft Tissue & Bone Tumors Department, National Cancer Institute, Mexico City, Mexico.ORCID 0000-0002-1302-2896
Julián Diaz-RicoSurgical Oncology Fellow, Surgical Department, National Cancer Institute, Mexico City, Mexico.
Ana Paulina Melendez-FernandezSurgical Oncology, Skin, Soft Tissue & Bone Tumors Department, National Cancer Institute, Mexico City, Mexico.
Constanza Palma-RebollarNational Cancer Institute, Mexico City, Mexico.
Kuauhyama Luna-OrtizSurgical Oncology Department of Head and Neck Surgery Department, National Cancer Institute, Mexico City, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retroperitoneal sarcomas are a rare and heterogeneous group of malignant neoplasms. The most frequent sarcoma in this location is liposarcoma; complete resection is the gold standard of treatment. To achieve this, a multivisceral resection is often necessary to reduce local recurrence. However, this approach must be balanced by the potential for added morbidity. This study aims to evaluate the platelet-albumin ratio as a predictor of morbidity risk. A retrospective review of the medical records of patients with retroperitoneal liposarcomas operated with curative intent at our institution between January 2010 and December 2020 was performed. The platelet-albumin ratio was calculated, and a cutoff point of 78.86 was determined to predict morbidity by receiver operating characteristic (ROC) curve analysis, divided into high-risk and low-risk groups with a sensitivity of 83% and a specificity of 71.6%. These risk groups were contrasted with the different demographic and evolution variables. One hundred thirty-six patients were analyzed, and 91 met the inclusion criteria; age at presentation was 52.55 years (SD 12.96), tumor size was 29.31 (SD 12.43), and 40.7% underwent multivisceral resections, identifying a difference between the presence of a high platelet/albumin ratio and the appearance of complications at 30 days with an OR of 8 (CI 1.0052 to 63.6698,

Indexed as

LiposarcomaMorbidityPlatelet/albumin ratioRetroperitoneal liposarcoma

Identifiers

PMID40337022
PMCPMC12052753

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.